Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 3636

1.

Hormone therapy can wait in PSA-only relapse.

Schmidt C.

J Natl Cancer Inst. 2014 Aug 13;106(8). pii: dju278. doi: 10.1093/jnci/dju278. Print 2014 Aug. No abstract available.

PMID:
25122737
[PubMed - indexed for MEDLINE]
2.

[Far remote results of radical prostatectomy in patients suffering localized and locally advanced prostatic cancer].

Grigorenko VN, Shamraev SN, Danilets RO, Bardin AV, Gurzhenko AIu, Pereta LV.

Klin Khir. 2014 Mar;(3):44-8. Russian.

PMID:
25098000
[PubMed - indexed for MEDLINE]
3.

Expected population impacts of discontinued prostate-specific antigen screening.

Gulati R, Tsodikov A, Etzioni R, Hunter-Merrill RA, Gore JL, Mariotto AB, Cooperberg MR.

Cancer. 2014 Jul 25. doi: 10.1002/cncr.28932. [Epub ahead of print]

PMID:
25065910
[PubMed - as supplied by publisher]
4.

Disease-specific outcomes of radical prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time.

Andersen S, Richardsen E, Nordby Y, Ness N, Størkersen O, Al-Shibli K, Donnem T, Bertilsson H, Busund LT, Angelsen A, Bremnes RM.

BMC Urol. 2014 Jun 14;14:49. doi: 10.1186/1471-2490-14-49.

PMID:
24929427
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Role of novel risk classification method, Prostate Cancer Risk Index (PRIX) for clinically localized prostate cancer after high-dose-rate interstitial brachytherapy as monotherapy.

Yoshida K, Yamazaki H, Nakamura S, Masui K, Kotsuma T, Akiyama H, Tanaka E, Yoshioka Y.

Anticancer Res. 2014 Jun;34(6):3077-81.

PMID:
24922676
[PubMed - indexed for MEDLINE]
6.

[CONs].

Sobue T.

Gan To Kagaku Ryoho. 2014 May;41(5):553-7. Japanese.

PMID:
24917002
[PubMed - indexed for MEDLINE]
7.

[Future perspectives on screening for prostate cancer - an experienced Urologist's viewpoint].

Ito K.

Gan To Kagaku Ryoho. 2014 May;41(5):545-52. Japanese.

PMID:
24917001
[PubMed - indexed for MEDLINE]
8.

Enzalutamide in metastatic prostate cancer before chemotherapy.

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators.

N Engl J Med. 2014 Jul 31;371(5):424-33. doi: 10.1056/NEJMoa1405095. Epub 2014 Jun 1.

PMID:
24881730
[PubMed - indexed for MEDLINE]
9.

DOC-2/DAB2 interacting protein status in high-risk prostate cancer correlates with outcome for patients treated with radiation therapy.

Jacobs C, Tumati V, Kapur P, Yan J, Hong D, Bhuiyan M, Xie XJ, Pistenmaa D, Yu L, Hsieh JT, Saha D, Kim DW.

Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):729-35. doi: 10.1016/j.ijrobp.2014.03.035. Epub 2014 May 24.

PMID:
24867541
[PubMed - indexed for MEDLINE]
10.

Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancer.

Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Hoffman KE, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL.

Clin Genitourin Cancer. 2014 Oct;12(5):e189-95. doi: 10.1016/j.clgc.2014.04.003. Epub 2014 May 9.

PMID:
24861952
[PubMed - in process]
11.

CtBP2 could promote prostate cancer cell proliferation through c-Myc signaling.

Zhang C, Gao C, Xu Y, Zhang Z.

Gene. 2014 Aug 1;546(1):73-9. doi: 10.1016/j.gene.2014.05.032. Epub 2014 May 14.

PMID:
24835310
[PubMed - indexed for MEDLINE]
12.

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer.

Tomioka A, Tanaka N, Yoshikawa M, Miyake M, Anai S, Chihara Y, Okajima E, Hirayama A, Hirao Y, Fujimoto K.

BMC Urol. 2014 Apr 29;14:33. doi: 10.1186/1471-2490-14-33.

PMID:
24773608
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

RE: Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.

Carlsson S, Roobol MJ, Schröder FH, Hugosson J, Auvinen A.

J Natl Cancer Inst. 2014 Apr 26;106(5). pii: dju079. doi: 10.1093/jnci/dju079. No abstract available.

PMID:
24771874
[PubMed - indexed for MEDLINE]
14.

Response.

Haines IE, Miklos GL.

J Natl Cancer Inst. 2014 Apr 26;106(5). pii: dju081. doi: 10.1093/jnci/dju081. No abstract available.

PMID:
24771873
[PubMed - indexed for MEDLINE]
15.

Obesity and Long-Term Survival after Radical Prostatectomy.

Chalfin HJ, Lee SB, Jeong BC, Freedland SJ, Alai H, Feng Z, Trock BJ, Partin AW, Humphreys E, Walsh PC, Han M.

J Urol. 2014 Apr 21. pii: S0022-5347(14)03421-1. doi: 10.1016/j.juro.2014.04.086. [Epub ahead of print]

PMID:
24769031
[PubMed - as supplied by publisher]
16.

Prostate cancer deaths and incident cases among American Indian/Alaska Native men, 1999-2009.

Hoffman RM, Li J, Henderson JA, Ajani UA, Wiggins C.

Am J Public Health. 2014 Jun;104 Suppl 3:S439-45. doi: 10.2105/AJPH.2013.301690. Epub 2014 Apr 22.

PMID:
24754659
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level.

Izumi K, Lin WJ, Miyamoto H, Huang CK, Maolake A, Kitagawa Y, Kadono Y, Konaka H, Mizokami A, Namiki M.

J Cancer Res Clin Oncol. 2014 Aug;140(8):1413-9. doi: 10.1007/s00432-014-1681-8. Epub 2014 Apr 19.

PMID:
24747988
[PubMed - indexed for MEDLINE]
18.

Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer.

Ritch CR, You C, May AT, Herrell SD, Clark PE, Penson DF, Chang SS, Cookson MS, Smith JA Jr, Barocas DA.

Urology. 2014 Jun;83(6):1309-15. doi: 10.1016/j.urology.2014.02.023. Epub 2014 Apr 18.

PMID:
24746665
[PubMed - indexed for MEDLINE]
19.

Efficacy and toxicity of external-beam radiation therapy for localised prostate cancer: a network meta-analysis.

Zhu Z, Zhang J, Liu Y, Chen M, Guo P, Li K.

Br J Cancer. 2014 May 13;110(10):2396-404. doi: 10.1038/bjc.2014.197. Epub 2014 Apr 15.

PMID:
24736585
[PubMed - indexed for MEDLINE]
20.

Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.

Angelergues A, Maillet D, Fléchon A, Ozgüroglu M, Mercier F, Guillot A, Le Moulec S, Gravis G, Beuzeboc P, Massard C, Fizazi K, de La Motte Rouge T, Delanoy N, Elaidi RT, Oudard S.

Eur J Cancer. 2014 Jun;50(9):1602-9. doi: 10.1016/j.ejca.2014.03.015. Epub 2014 Apr 8.

PMID:
24725337
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk